Kintara Therapeutics is a clinical stage, biopharmaceutical company. Co.'s key candidates are: VAL-083, a DNA-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late-stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer. Co. is also conducting open-label, biomarker driven studies in methyl guanine methyltransferase-unmethylated GBM. REM-001 consists of an active pharmaceutical ingredient in a lipid formulation. The KTRA stock yearly return is shown above.
The yearly return on the KTRA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the KTRA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|